[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ECSP045193A - "nuevos compuestos heterociclicos, activos como inhibidores de beta-lactamasas" - Google Patents

"nuevos compuestos heterociclicos, activos como inhibidores de beta-lactamasas"

Info

Publication number
ECSP045193A
ECSP045193A EC2004005193A ECSP045193A ECSP045193A EC SP045193 A ECSP045193 A EC SP045193A EC 2004005193 A EC2004005193 A EC 2004005193A EC SP045193 A ECSP045193 A EC SP045193A EC SP045193 A ECSP045193 A EC SP045193A
Authority
EC
Ecuador
Prior art keywords
lactamasas
inhibitors
beta
active
compounds
Prior art date
Application number
EC2004005193A
Other languages
English (en)
Inventor
Jozsef Aszodi
Claude Fromentin
Maxime Lampilas
David Alan Rowlands
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27619669&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP045193(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of ECSP045193A publication Critical patent/ECSP045193A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995Pyrazines or piperazines forming part of bridged ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La invención se refiere a la utilización de compuestos de fórmula (I),y sus sales farmacéuticamente aceptables, en la preparación de un medicamento destinado a inhibir la producción de b- lactamasas por bacterias patógenas.
EC2004005193A 2002-01-28 2004-07-15 "nuevos compuestos heterociclicos, activos como inhibidores de beta-lactamasas" ECSP045193A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0200951A FR2835186B1 (fr) 2002-01-28 2002-01-28 Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases

Publications (1)

Publication Number Publication Date
ECSP045193A true ECSP045193A (es) 2004-08-27

Family

ID=27619669

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2004005193A ECSP045193A (es) 2002-01-28 2004-07-15 "nuevos compuestos heterociclicos, activos como inhibidores de beta-lactamasas"

Country Status (45)

Country Link
US (4) US7612087B2 (es)
EP (2) EP2279737B1 (es)
JP (1) JP4472346B2 (es)
KR (1) KR100979079B1 (es)
CN (3) CN101406471A (es)
AR (2) AR038234A1 (es)
AT (1) ATE484281T1 (es)
AU (1) AU2003214335B2 (es)
BE (1) BE2016C069I2 (es)
BR (1) BRPI0307267B8 (es)
CA (1) CA2474043C (es)
CL (1) CL2011000009A1 (es)
CO (1) CO5601014A2 (es)
CR (2) CR7387A (es)
CY (3) CY1111061T1 (es)
DE (1) DE60334527D1 (es)
DK (2) DK2279737T3 (es)
EA (1) EA007220B1 (es)
EC (1) ECSP045193A (es)
ES (2) ES2356813T3 (es)
FR (1) FR2835186B1 (es)
HK (2) HK1077205A1 (es)
HR (1) HRP20040686B1 (es)
HU (1) HUS1600055I1 (es)
IL (1) IL163167A (es)
JO (1) JO2646B1 (es)
LT (1) LTC1480644I2 (es)
MA (1) MA26351A1 (es)
MX (1) MXPA04006621A (es)
MY (1) MY140638A (es)
NL (1) NL300847I2 (es)
NO (2) NO335195B1 (es)
NZ (1) NZ533936A (es)
OA (1) OA12761A (es)
PE (1) PE20030969A1 (es)
PL (1) PL220725B1 (es)
PT (2) PT2279737E (es)
RS (1) RS52137B (es)
SI (2) SI2279737T1 (es)
TN (1) TNSN04137A1 (es)
TW (1) TWI293071B (es)
UA (1) UA80271C2 (es)
UY (1) UY27626A1 (es)
WO (1) WO2003063864A2 (es)
ZA (1) ZA200405607B (es)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2812635B1 (fr) * 2000-08-01 2002-10-11 Aventis Pharma Sa Nouveaux composes heterocycliques, preparation et utilisation comme medicaments notamment comme anti- bacteriens
FR2835186B1 (fr) * 2002-01-28 2006-10-20 Aventis Pharma Sa Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
FR2844273B1 (fr) 2002-09-05 2008-04-04 Aventis Pharma Sa Nouveaux composes heterocycliques, procede et intermediaires de preparation et utilisation comme medicament, notamment comme inhibiteurs de beta-lactamases et anti-bacteriens.
FR2848210B1 (fr) * 2002-12-06 2007-10-19 Aventis Pharma Sa Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens et inhibiteurs de beta-lactamases
US7439253B2 (en) * 2002-12-06 2008-10-21 Novexel Heterocyclic compounds, their preparation and their use as medicaments, in particular as antibacterials and beta-lactamase inhibitors
US8900637B2 (en) * 2005-12-02 2014-12-02 Lupin Limited Stable taste masked formulations of cephalosporins
PT2308874E (pt) * 2005-12-07 2013-04-26 Basilea Pharmaceutica Ag Monobactamas ligadas por pontes, úteis como inibidores de beta-lactamase
US20090298878A1 (en) * 2006-07-14 2009-12-03 Akira Matsumura Oxime compounds and the use thereof
MX2009004290A (es) * 2006-10-23 2009-07-27 Irm Llc Inhibidores de proteasas de catepsina.
ES2422603T3 (es) * 2007-05-31 2013-09-12 Shionogi & Co Compuestos oxiimino y el uso de estos
FR2921060B1 (fr) * 2007-09-14 2012-06-15 Novexel Nouveau procede de preparation d'une piperidine disubsituee et nouveaux intermediaires
EP2666774B1 (en) * 2008-01-18 2015-01-07 Merck Sharp & Dohme Corp. Beta-lactamase Inhibitors
WO2009114921A1 (en) * 2008-03-17 2009-09-24 Dmitrienko Gary I INHIBITORS OF CLASS B AND CLASS D β-LACTAMASES
FR2930553B1 (fr) * 2008-04-29 2010-05-21 Novexel Composes azabicycliques, leur preparation et leur utilisation comme medicaments, notamment inhibiteurs de beta-lactamases
EP2346820B1 (en) * 2008-06-11 2013-02-13 Shionogi & Co., Ltd. Oxycarbamoyl compounds and the use thereof
FR2936798B1 (fr) * 2008-10-03 2012-09-28 Novexel Nouveaux composes heterocycliques azotes, leur preparation et leur utilisation comme medicaments antibacteriens.
FR2936951B1 (fr) * 2008-10-10 2010-12-03 Novexel Nouvelles combinaisons de composes heterocycliques azotes antibacteriens avec d'autres composes antibacteriens et leur utilisation comme medicaments
FR2937034B1 (fr) * 2008-10-10 2012-11-23 Novexel Nouveaux composes heterocycliques azotes, leur preparation et leur utilisation comme medicaments antibacteriens
AU2014244235B2 (en) * 2009-10-09 2016-04-21 Pfizer Ireland Pharmaceuticals Polymorphic and pseudopolymorphic forms of a pharmaceutical compound
FR2951171A1 (fr) 2009-10-09 2011-04-15 Novexel Nouveau sel de sodium d'un compose azabicyclique sous forme enantiomere cristallisee et nouvelles formes polymorphes et pseudopolymorphes ainsi que leur preparation
RU2599791C2 (ru) 2010-08-10 2016-10-20 Ремпекс Фармасьютикэлз, Инч. Циклические бороновые кислотно-эфирные производные и их использование в терапии
US8772490B2 (en) 2010-12-22 2014-07-08 Meiji Seika Pharma Co., Ltd. Optically active diazabicyclooctane derivatives and process for preparing the same
WO2012086241A1 (ja) * 2010-12-22 2012-06-28 Meiji Seikaファルマ株式会社 光学活性なジアザビシクロオクタン誘導体およびその製造法
TWI565706B (zh) * 2011-06-17 2017-01-11 阿斯特捷利康公司 用於製備包括反-7-酮基-6-(磺酸氧基)-1,6-二氮雜雙環[3,2,1]辛烷-2-甲醯胺之雜環化合物及其鹽類之方法
CA2833241C (en) * 2011-08-27 2015-05-12 Wockhardt Limited 1,6-diazabicyclo [3,2,1] octan-7-one derivatives and their use in the treatment of bacterial infections
US9102683B2 (en) 2011-08-29 2015-08-11 University Of Utah Research Foundation Heterocyclic compounds
US20130053565A1 (en) * 2011-08-29 2013-02-28 University Of Utah Research Foundation Substituted 3-piperidone compounds
US9012491B2 (en) 2011-08-31 2015-04-21 Rempex Pharmaceuticals, Inc. Heterocyclic boronic acid ester derivatives and therapeutic uses thereof
US8969567B2 (en) * 2011-09-13 2015-03-03 Wockhardt Ltd. Nitrogen containing compounds and their use
RU2569307C1 (ru) * 2011-09-13 2015-11-20 Вокхардт Лимитед Азотсодержащие соединения и их применение
US8796257B2 (en) 2011-12-02 2014-08-05 Naeja Pharmaceutical Inc. Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors
US9505761B2 (en) 2011-12-02 2016-11-29 Fedora Pharmaceuticals Inc. Bicyclic compounds and their use as antibacterial agents and beta-lactamase inhibitors
AU2013237869A1 (en) 2012-03-30 2014-10-23 Cubist Pharmaceuticals, Inc. Isoxazole beta-lactamase inhibitors
US8916709B2 (en) 2012-03-30 2014-12-23 Cubist Pharmaceuticals, Inc. 1,2,4-oxadiazole and 1,2,4-thiadiazole β-lactamase inhibitors
EP2831075B1 (en) 2012-03-30 2017-11-08 Merck Sharp & Dohme Corp. 1,3,4-oxadiazole and 1,3,4-thiadiazole beta-lactamase inhibitors
US8969570B2 (en) 2012-03-30 2015-03-03 Cubist Pharmaceuticals, Inc. Beta-lactamase inhibitors
AR090539A1 (es) * 2012-04-02 2014-11-19 Astrazeneca Ab COMPUESTOS INHIBIDORES DE b LACTAMASA
US9156858B2 (en) 2012-05-23 2015-10-13 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
CA2874279C (en) 2012-05-30 2021-03-16 Meiji Seika Pharma Co., Ltd. Diazabicyclooctane derivatives useful as .beta.-lactamase inhibitor and process for preparing the same
US10561675B2 (en) 2012-06-06 2020-02-18 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
ES2672100T3 (es) * 2012-08-25 2018-06-12 Wockhardt Limited Derivados de 1,6-diazabiciclo[3,2,1]octano-7-ona y su uso en el tratamiento de infecciones bacterianas
UA111925C2 (uk) * 2012-12-11 2016-06-24 Федора Фармасьютікалз Інк. БІЦИКЛІЧНІ СПОЛУКИ ТА ЇХ ВИКОРИСТАННЯ ЯК АНТИБАКТЕРІАЛЬНИХ АГЕНТІВ ТА ІНГІБІТОРІВ β-ЛАКТАМАЗИ
US9241947B2 (en) 2013-01-04 2016-01-26 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
CN104994844A (zh) 2013-01-04 2015-10-21 莱姆派克斯制药公司 硼酸衍生物及其治疗用途
BR112015016002A2 (pt) 2013-01-04 2017-07-11 Rempex Pharmaceuticals Inc compostos, composições farmacêuticas, complexos químicos e respectivos usos e método para tratar ou prevenir infecção bacteriana
US9101638B2 (en) 2013-01-04 2015-08-11 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
WO2014152996A1 (en) 2013-03-14 2014-09-25 Cubist Pharmaceuticals, Inc. Crystalline form of a beta-lactamase inhibitor
NZ718009A (en) 2013-09-24 2018-03-23 Meiji Seika Pharma Co Ltd Process for producing diazabicyclooctane derivative and intermediate thereof
WO2015051101A1 (en) 2013-10-02 2015-04-09 Cubist Pharmaceuticals, Inc. B-lactamase inhibitor picoline salt
CN105612159A (zh) 2013-10-08 2016-05-25 明治制果药业株式会社 二氮杂二环辛烷衍生物的结晶及其制备方法
KR20160115941A (ko) * 2014-02-20 2016-10-06 욱크하르트 리미티드 항세균제를 포함하는 제약학적 조합
CN103896936A (zh) * 2014-03-20 2014-07-02 西安交通大学 (5s,6r)氯唑西林青霉噻唑酸盐及其制备方法和应用
WO2015171398A1 (en) 2014-05-05 2015-11-12 Rempex Pharmaceuticals, Inc. Salts and polymorphs of cyclic boronic acid ester derivatives and therapeutic uses thereof
LT3140310T (lt) 2014-05-05 2019-11-25 Rempex Pharmaceuticals Inc Boronato druskų sintezė ir jų panaudojimas
JP6672176B2 (ja) 2014-05-19 2020-03-25 レンペックス・ファーマシューティカルズ・インコーポレイテッド ボロン酸誘導体およびその治療的使用
CN104059083B (zh) * 2014-05-27 2017-01-04 浙江工业大学 一种手性二环己内酰胺类化合物的不对称合成方法
JP6700203B2 (ja) 2014-07-01 2020-05-27 レンペックス・ファーマシューティカルズ・インコーポレイテッド ボロン酸誘導体およびその治療的使用
TWI690317B (zh) 2014-11-17 2020-04-11 英商安特西醫療有限公司 用於治療抗藥性細菌感染之組合療法
WO2016081297A1 (en) 2014-11-18 2016-05-26 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
SG11201704576SA (en) 2014-12-05 2017-07-28 Meiji Seika Pharma Co Ltd Method for producing crystals of diazabicyclooctane derivative and stable lyophilized preparation
US20180051041A1 (en) 2015-03-17 2018-02-22 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
CN107580595B (zh) * 2015-05-07 2020-09-18 拜欧蒂姆公司 杂环化合物及它们在预防或治疗细菌感染中的应用
MX2017013792A (es) * 2015-09-16 2018-07-06 Xuanzhu Pharma Co Ltd INHIBIDORES DE íŸ-LACTAMASA Y USOS DE LOS MISMOS.
US9951072B2 (en) 2015-10-02 2018-04-24 Legochem Biosciences, Inc. Compositions and methods for inhibiting beta-lactamase
WO2017156458A1 (en) 2016-03-11 2017-09-14 University Of South Florida Beta-lactamase inhibitors, formulations, and uses thereof
ES2734773T3 (es) 2016-05-27 2019-12-11 Valoralia I Mas D Sl Compuestos de dihidrooxadiazina para tratar infecciones y cáncer
ES2894251T3 (es) 2016-06-30 2022-02-14 Qpex Biopharma Inc Derivados de ácido borónico y usos terapéuticos de los mismos
CN106279163A (zh) * 2016-08-12 2017-01-04 上海龙翔生物医药开发有限公司 一种合成阿维巴坦及其中间体光学异构体的方法
CN107789355B (zh) * 2016-09-07 2022-04-12 湘北威尔曼制药股份有限公司 含有哌拉西林的复方药物组合物及其应用
MA46242A (fr) 2016-09-16 2019-07-24 Entasis Therapeutics Ltd Composés inhibiteurs de bêta-lactamase
JOP20190061A1 (ar) 2016-09-28 2019-03-26 Novartis Ag مثبطات بيتا-لاكتاماز
CN106699756B (zh) * 2016-12-30 2019-10-29 淄博鑫泉医药技术服务有限公司 β内酰胺酶抑制剂阿维巴坦的合成方法
US20200017496A1 (en) 2017-02-06 2020-01-16 Mutabilis Novel heterocyclic compounds and their use in preventing or treating bacterial infections
PE20200333A1 (es) 2017-05-08 2020-02-14 Entasis Therapeutics Inc Compuestos y metodos para tratar infecciones bacterianas
WO2018234962A1 (en) 2017-06-20 2018-12-27 Wockhardt Limited PROCESS FOR O-SULFONATION OF 1,6-DIAZABICYCLO [3.2.1] OCTANE COMPOUNDS
JP7377545B2 (ja) 2017-10-11 2023-11-10 キューペックス バイオファーマ, インコーポレイテッド ボロン酸誘導体およびその合成
CN109678856B (zh) * 2017-10-18 2020-09-25 新发药业有限公司 一种阿维巴坦中间体的制备方法
WO2019093450A1 (ja) * 2017-11-10 2019-05-16 塩野義製薬株式会社 ジアザビシクロオクタン誘導体
CA3097127A1 (en) 2018-04-20 2019-10-24 Qpex Biopharma, Inc. Boronic acid derivatives and therapeutic uses thereof
US11905286B2 (en) 2018-08-09 2024-02-20 Antabio Sas Diazabicyclooctanones as inhibitors of serine beta-lactamases
CN109942579B (zh) * 2019-04-18 2021-06-22 成都千禧莱医药科技有限公司 β-内酰胺酶抑制剂含脲双环化合物及其制备方法和应用
EP4146650A4 (en) * 2020-09-01 2024-01-17 Ningxia Academy of Agriculture and Forestry Sciences BETA-LACTAMASE INHIBITORS AND THEIR PRODUCTION
WO2022047790A1 (en) * 2020-09-07 2022-03-10 Ningxia Academy Of Agriculture And Forestry Sciences Amidine substituted bicyclic compounds, their preparation, their use as antibacterial agents and beta-lactamase inhibitors
WO2023060369A1 (en) * 2021-10-11 2023-04-20 Ningxia Academy Of Agriculture And Forestry Sciences Novel carbimidate substituted bicyclic compounds and their use as beta-lactamase inhibitors
CN116375706A (zh) * 2023-02-22 2023-07-04 时森海(杭州)医药科技有限公司 阿维巴坦钠关键中间体及其制备方法

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0260057A3 (en) 1986-09-02 1989-02-01 The University Of Melbourne 2-oxo-4-carboxy-pyrimidines
WO1990015058A1 (en) 1989-06-09 1990-12-13 The Upjohn Company Heterocyclic amines having central nervous system activity
FR2676230B1 (fr) 1991-05-07 1993-08-27 Centre Nat Rech Scient Nouveaux derives de pyrrolo [1,4]-benzodiazepines, leur procede de preparation et medicaments les contenant.
JPH05339263A (ja) 1992-06-08 1993-12-21 Wakunaga Pharmaceut Co Ltd ジヒドロピリジン誘導体
ES2182847T3 (es) 1993-09-29 2003-03-16 Nabi Nucleosidos y nucleotidos de anillo expandido.
DE69416869T2 (de) * 1993-12-29 1999-07-01 Pfizer Inc., New York, N.Y. Diazabicyclische neurokinin antagonisten
EP0702004A2 (de) * 1994-09-15 1996-03-20 Ciba-Geigy Ag 2,9-Diamino- und 2-amino-8-carbamoyl-4-hydroxy-alkansäureamid-derivative
GB9505538D0 (en) 1995-03-18 1995-05-03 Ciba Geigy Ag New compounds
SE9504618D0 (sv) 1995-12-22 1995-12-22 Astra Ab New Compounds
BR9612426A (pt) * 1996-01-03 1999-07-13 Smithkline Beecham Plc Derivados carbomoilóxi e sua aplicação como antibacterianos
UA51716C2 (uk) 1996-07-08 2002-12-16 Авентіс Фармасьютікалз Продактс Інк. Сполуки, що мають гіпотензивну, кардіопротекторну, анти-ішемічну та антиліполітичну властивості, фармацевтична композиція та способи лікування
DE19627431A1 (de) 1996-07-08 1998-01-15 Bayer Ag Heterocyclisch kondensierte Pyridine
HUP0001741A3 (en) * 1996-08-02 2000-11-28 Smithkline Beecham Plc Azabicyclic carbamoyloxy mutilin derivatives for antibacterial use, process for preparing them, pharmaceuticals contg. them and their use
TW527355B (en) 1997-07-02 2003-04-11 Bristol Myers Squibb Co Inhibitors of farnesyl protein transferase
US5994340A (en) * 1997-08-29 1999-11-30 Synphar Laboratories, Inc. Azetidinone derivatives as β-lactamase inhibitors
US6197339B1 (en) 1997-09-30 2001-03-06 Pharmacia & Upjohn Company Sustained release tablet formulation to treat Parkinson's disease
UY25225A1 (es) * 1997-10-29 2000-12-29 Smithkline Beecham Plc Derivados de pleuromutilina utiles como agentes antimicrobianos
WO1999052875A1 (en) 1998-04-08 1999-10-21 Takeda Chemical Industries, Ltd. Amine compounds, their production and their use as somatostatin receptor antagonists or agonists
WO2000000479A1 (en) 1998-06-30 2000-01-06 Du Pont Pharmaceuticals Company 1,3-benzodiazepin-2-ones and 1,3-benzoxazepin-2-ones useful as hiv reverse transcriptase inhibitors
GB9818731D0 (en) 1998-08-27 1998-10-21 Univ Portsmouth Compounds
CN1285588C (zh) 1998-12-18 2006-11-22 先灵公司 法尼基蛋白转移酶抑制剂
CO5180550A1 (es) 1999-04-19 2002-07-30 Smithkline Beecham Corp Inhibidores de fab i
CA2386517A1 (en) 1999-10-07 2001-04-12 Takeda Chemical Industries, Ltd. Amine derivatives
EP1288216A1 (en) 2000-04-18 2003-03-05 Sumitomo Pharmaceuticals Company, Limited Tricyclic quinazolinediones
FR2812635B1 (fr) * 2000-08-01 2002-10-11 Aventis Pharma Sa Nouveaux composes heterocycliques, preparation et utilisation comme medicaments notamment comme anti- bacteriens
ATE361750T1 (de) 2001-02-22 2007-06-15 Univ London Pharmacy Indoline und tetrahydro-chinoline als prodrugs zur tumorbehandlung
FR2825705B1 (fr) 2001-06-08 2005-05-20 Aventis Pharma Sa Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens
FR2835186B1 (fr) * 2002-01-28 2006-10-20 Aventis Pharma Sa Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
US7439253B2 (en) * 2002-12-06 2008-10-21 Novexel Heterocyclic compounds, their preparation and their use as medicaments, in particular as antibacterials and beta-lactamase inhibitors

Also Published As

Publication number Publication date
JP4472346B2 (ja) 2010-06-02
US20110245254A1 (en) 2011-10-06
PT2279737E (pt) 2013-02-01
IL163167A (en) 2010-04-15
TNSN04137A1 (fr) 2007-03-12
UY27626A1 (es) 2003-08-29
EP2279737A1 (fr) 2011-02-02
CA2474043A1 (fr) 2003-08-07
PT1480644E (pt) 2011-01-17
JP2005523897A (ja) 2005-08-11
CR20120356A (es) 2012-10-05
DK1480644T3 (da) 2011-01-24
NO335195B1 (no) 2014-10-20
CN101406471A (zh) 2009-04-15
SI2279737T1 (sl) 2013-07-31
RS52137B (en) 2012-08-31
ES2356813T3 (es) 2011-04-13
NO2016024I2 (no) 2016-12-15
FR2835186A1 (fr) 2003-08-01
EP1480644A2 (fr) 2004-12-01
WO2003063864A3 (fr) 2004-03-11
CY2016042I1 (el) 2017-03-15
PE20030969A1 (es) 2003-12-12
TW200303305A (en) 2003-09-01
KR100979079B1 (ko) 2010-08-31
OA12761A (fr) 2006-07-04
AR038234A1 (es) 2005-01-05
ATE484281T1 (de) 2010-10-15
CY2016042I2 (el) 2017-03-15
NZ533936A (en) 2007-05-31
DE60334527D1 (de) 2010-11-25
TWI293071B (en) 2008-02-01
AU2003214335B2 (en) 2007-04-05
CY1111061T1 (el) 2015-06-11
HUS1600055I1 (hu) 2017-01-30
CN100563653C (zh) 2009-12-02
WO2003063864A2 (fr) 2003-08-07
PL371601A1 (en) 2005-06-27
NL300847I2 (es) 2017-01-03
MY140638A (en) 2010-01-15
UA80271C2 (uk) 2007-09-10
US20050020572A1 (en) 2005-01-27
US20090215747A1 (en) 2009-08-27
LTPA2016037I1 (lt) 2017-01-10
PL220725B1 (pl) 2015-12-31
HK1077205A1 (en) 2006-02-10
CR7387A (es) 2010-10-25
HK1105864A1 (en) 2008-02-29
CL2011000009A1 (es) 2011-03-25
BR0307267A (pt) 2004-12-07
HRP20040686A2 (en) 2004-12-31
US20100048528A1 (en) 2010-02-25
NO20043587L (no) 2004-08-27
ZA200405607B (en) 2005-09-28
CN100482225C (zh) 2009-04-29
ES2401855T3 (es) 2013-04-25
HRP20040686B1 (hr) 2013-02-28
SI1480644T1 (sl) 2011-03-31
NO2016024I1 (no) 2016-12-15
AR100790A2 (es) 2016-11-02
LTC1480644I2 (lt) 2018-09-10
YU65804A (sh) 2006-08-17
EA007220B1 (ru) 2006-08-25
CY1114417T1 (el) 2016-08-31
EA200400981A1 (ru) 2005-02-24
CN1994301A (zh) 2007-07-11
DK2279737T3 (da) 2013-02-11
FR2835186B1 (fr) 2006-10-20
US7612087B2 (en) 2009-11-03
CO5601014A2 (es) 2006-01-31
CA2474043C (fr) 2011-08-02
BE2016C069I2 (es) 2022-05-17
MXPA04006621A (es) 2004-10-04
BRPI0307267B1 (pt) 2016-02-10
KR20040081473A (ko) 2004-09-21
JO2646B1 (en) 2012-06-17
CN1655781A (zh) 2005-08-17
EP2279737B1 (fr) 2012-10-31
BRPI0307267B8 (pt) 2021-05-25
MA26351A1 (fr) 2004-10-01
EP1480644B1 (fr) 2010-10-13

Similar Documents

Publication Publication Date Title
ECSP045193A (es) "nuevos compuestos heterociclicos, activos como inhibidores de beta-lactamasas"
CU23105A3 (es) DERIVADOS NOVEDOSOS DEL áCIDO AMINODICARBOXILICO CON PROPIEDADES FARMACéUTICAS
SE0202462D0 (sv) Novel use
IL173062A0 (en) Substituted 2-aminotetralin for the treatment of depression
BR0210507A (pt) Azaindóis
SE0200979D0 (sv) New compounds
GEP20125538B (en) 2,3-dihydrobenzo(1,4) dioxin-2-ylmethyl derivatives as alpha2c antagonists for use in the treatment of peripheric and central nervous system diseases
NO20065904L (no) Terapeutiske forbindelser
SE0202429D0 (sv) Novel Compounds
UY28360A1 (es) Nuevos compuestos
MY140630A (en) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
SE0301701D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
TW200640465A (en) New pharmaceutically active compounds for the treatment of respiratory diseases
TW200504030A (en) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
AR030503A1 (es) Antibioticos de cefalosporina y prodrogas de los mismos
SE0102058D0 (sv) New Salts II
ATE491709T1 (de) Pyrrolidinohydrochinazoline
BR122015020406B8 (pt) uso de compostos de formula i como inibidores de beta-lactamases e composições farmaceuticas
ITMI20041822A1 (it) "agente terapeutico utile per il trattamento di neoplasie plasmacellulari"
SE0401716D0 (sv) New compounds
ATE259802T1 (de) Verbindungen mit antithrombotischer wirkung
TW200614991A (en) Novel compounds
TW200626583A (en) Novel compounds